Preliminary eventuates from Dendre...

Preliminary eventuates from Dendreon Corporation's (Seattle, WA) analysis of a randomized, double-blind, placebo-controlled, Phase 3 contemplation of Provenge (APC 8015), an anticancer vaccine, exhibits that subjects who have a Gleason score of 7 or les significantly benefited from the treatment. The trial involved 127 men with late stage, metastatic, hormone-resistant prostate cancer, 82 of whom received the subject of attention drug. Subjects were randomized to receive three vaccinations of the research drug or placebo throughout a four-week period. The primary endpoint for the inquiry was the time to objective